fc

Fc receptors bridge antibodies and immune cells. Biointron highlights their roles in immune signaling and therapeutic antibody function.

FcRn is critical for IgG recycling and half-life extension. Biointron explores its biology and applications in designing durable therapeutic antibodies.

Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.

Fc-mediated antibody effector functions play an important role in the humoral immune response and form a necessary link between innate and adaptive immunity. The constant (Fc) region is the tail portion of an antibody that interacts with other components of the immune system, such as immune cells and complement proteins. Well-known functions include opsonization, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement activation.

The 4th Fc-Mediated Function Summit in Boston showcased Fc engineering advances. Biointron reports key insights driving next-generation antibody therapeutics.

Fab, F(ab’)2, and Fc fragments expand antibody applications. Biointron explains their structures and how they advance diagnostics, imaging, and therapeutic innovation.

Biointron is thrilled to be part of the 4th Fc-Mediated Function Summit, a pivotal event focusing on the latest developments in FcRn, FcγR, and IgG, aiming to enhance related therapeutic applications. This unique conference, happening in Boston from April 16-18, 2024, will be gathering over 80 specialists in the field to share insights on molecular engineering and clinical outcomes.